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Following the millennium shift, the market for e-
cigarettes has expanded logarithmically, and today there
are hundreds of e-cigarette products and thousands of fla-
vor variations. This increase in e-cigagette use contrasts to
a major and continuing decrease in cigarette smoking seen
in most westernized countries for some decades [1]. It
seems that the marketing of e-cigarettes is less active in
middle and low level income countries, as exemplified in a
paper from Egypt in this issue of Respiratory Research [2].
Are e-cigs safe, or safe enough, is a controversy also
in the medical society. Particularly the public health
community seems to be divided, and safety and efficacy
aspects of e-cigarettes for smoking cessation have been
unclear. Among public health professionals, particularly
in the UK [3], there is an opinion favoring the use of e-
cigarettes as a smoking cessation tool among smokers,
while others strongly believe the contrary [4]. So, who
are those who use e-cigarettes? Is it middle aged or
elderly smokers that want to quit smoking? According
to the 2012 Eurobarometer survey, about 30 million
adults in the 27 EU countries that year used or had
used e-cigarettes [6], and the greatest proportion of
ever users of e-cigarettes was found among subjects
aged 15–24 years followed by those aged 25–39 years,
further, this proportion was considerably greater among
heavy smokers compared to light smokers.
And what about the usefulness of e-cigarettes in pro-
moting smoking cessation, are they useful? A recently
published meta-analysis and systematic review ended up
in an opposite conclusion [7]. E-cigarette use was found to
be associated with less quitting among smokers compared
to quitting among smokers not having used e-cigarettes.
The authors concluded that e-cigarettes should so far not
be recommended for effective smoking cessation. In con-
trast to aiming at primary and secondary prevention of
disease, subjects with already severe malignant smoking
associated disease seem to be prone to switch to e-
cigarettes, as demonstrated by one paper in this issue of
Respiratory Research from the UK [8].
These controversies beclouding the effectiveness and
safety of e-cigarettes serve as an important opportunity
to reecho about the availability of very effective and safe
drugs for the pharmaceutical treatment of nicotine
addiction, which according to WHO, is a disease and
should be treated accordingly. It is astonishing to find
out that the two RCTs that were used to prove the
effectiveness of e-cigarettes as a smoking cessation
tool actually showed smoking abstinence (7 %) at 6
and 12 months (9–12 %) [9–11] lower than that of
the placebo (10 %) in the main clinical trials done for
the effectiveness of pharmaceutical therapy [12–15].
Abstinence with varenicline and bupropion in the
same trials were 30 and 21 % at 6 months and 22 %
and, 15 % at 12 months accordingly [14, 15]. In the
UK, where e-cigarette use as a smoking cessation tool
has been endorsed by the Royal College of Physicians
of London ASH and NHS, there is currently an increasing
use of e-cigarette as a smoking cessation tool and a de-
crease of the use of NRTs. Majority of health professionals
are not trained in smoking cessation and hence have not
adopted it in their everyday practice. Shouldn’t this be a
concern that instead of health professionals going through
training and conducting smoking cessation through scien-
tifically endorsed best practices they engage in short cut
advising on use of e-cigarettes for smoking cessation with
no sufficient scientific backing?
Besides, the media’s widely quoted e-cigarettes being
considerably less harmful to health as compared to con-
ventional cigarettes [3–5] do not take into account long-
term risks where we have no data. Although studies on
the pulmonary effects of e-cigarettes are still limited, short-
term negative effects of e-cigarettes are already emerging.
As the airway epithelium provides the first line of defense
against all inhaled exposures [16], e-cigarette use has lead
to decreased exhaled NO and increased airway resistance
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in humans [24]. Moreover, the liquid flavors and chemicals
used in e-cigarettes are in thousands with their detailed
identification and effects being subject of research.
Some early studies have found that levels of harmful
constituents in e-cigarettes are lower than in ordinary
cigarette smoke [17] and thus lead to the impression
that e-cigarettes are unlikely to cause serious public
health concerns, particularly relative to normal tobacco
cigarettes, a statement made also by the authors of one
publication in this issue of Respiratory Research [18],
who also discuss ethical considerations of e-cigarette
use for tobacco harm reduction. However, flavorings in
e-cigarettes have cytotoxic effects in cell models [19], and
another paper in this issue provides further evidence of
pathological effects on the epithelium [20] with detrimen-
tal consequences for airway surface liquid homeostasis in
habitual e-cigarette users [20]. In another study also pre-
sented in this issue several harmful chemicals including
carcinogens were identified in e-cigarette vapour extract,
which caused an increase in expression of CD11b and
CD66b, and further, increased release of MMP-9. The
authors conclude that pro-inflammatory responses
from human neutrophils raise concerns over the safety
of e-cigarette use [21], further e-cigarettes have an im-
pact on respiratory flow resistance, impedance, and ex-
haled NO [22]. These are excellent examples of
research about compositions, concentrations and ef-
fects of the e-cigarette liquids. Although the concentra-
tions of nicotine in e-cigarettes are lower than in
ordinary cigarettes, the use of e-cigarettes may result in
nicotine dependence and thus also use of other tobacco
products such as ordinary cigarettes [23]. As preventing
young people from taking up smoking is a major
public health issue, the focus of the marketing of e-
cigarettes on young people raises severe concerns
[23]. Further, inhaled nicotine in itself has probably
health effects also on humans, as shown in animal
models. Thus the recommended restriction or ban-
ning of e-cigarettes by the Forum of International Re-
spiratory Societies (FIRS) is thus reasonable [24].
Hence we encourage the training of health profes-
sionals in smoking cessation and the implementation
of the combination of approved pharmaceutical ther-
apies and behavioral counseling in everyday practice
until there is valid information available about the
safety of e-cigarettes.
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